PHILADELPHIA – September 03, 2009 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug ...

WASHINGTON, May 7 -- Shire plc(LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented today at a major scientific meeting findings from analyses of pivotal trial results ...

Shire Receives Approvable Letter From FDA for Intuniv (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, June 21, 2007 -- ...

FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents First once-daily nonstimulant to be ...

The first selective alpha-2A adrenergic receptor agonist licensed for the treatment of ADHD in the EU Shire (LSE: SHP, NASDAQ: SHPG) today announced that the European Commission granted Marketing ...

Sept. 4 -- THURSDAY, Sept. 3 (HealthDay News) -- Intuniv (guanfacine) has been approved by the U.S. Food and Drug Administration to treat Attention-Deficit ...

Teva Pharmaceutical Industries Ltd is seeking to disqualify two expert witnesses hired by plaintiffs who are accusing one of the drugmaker's units of illegally delaying the release of a generic ...

Shire Plc. SHPG announced that its Japanese partner Shionogi & Co., Ltd submitted a new drug application (NDA) for the manufacture and marketing of Intuniv (guanfacine hydrochloride extended release) ...

A federal judge on Wednesday declined to certify a class of consumers alleging Shire PLC entered into an improper deal to delay the release of a generic, cheaper version of the ADHD drug Intuniv, ...

NEW ORLEANS British drug maker Shire presented late-stage clinical study data at a psychiatric meeting Friday indicating that administration of one of its drugs along with stimulants provided symptom ...

"The approval of INTUNIV marks a significant advance in the treatment of ADHD in children and adolescents in Europe. Previously, physicians had only one licensed non-stimulant option for these ...

INTUNIV (guanfacine) 1mg, 2mg, 3mg, 4mg ext-rel tablets by Shire The FDA has approved once-daily Intuniv (guanfacine extended-release tablets, from Shire), a selective alpha-2A adrenergic receptor ...